Anvendelse af NKp46 til forebyggelse af type 1-diabetes

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Original languageEnglish
Patent numberDK2408468T3
IPCC07K 16/ 28 A I
Priority date18/03/10
StatePublished - 21 Jul 2014

Cite this